The initiation from Canaccord Genuity adds to a growing wall of bullish analyst coverage, but the real story is the convergence of insider buying and institutional accumulation against a 55.8% short interest. This setup creates a high-risk, high-reward squeeze opportunity, but the pre-revenue biotech profile means any catalyst miss could be severe.
Price Chart
Executive Summary
Canaccord Genuity initiated coverage on QNRX (Quoin Pharmaceuticals Ltd.) with a Buy rating and an $18 price target, implying 361.5% upside from the current $3.90 close. The firm has a 47% accuracy rate on 1,623 calls with a 3.2% average return. The consensus across 10 analysts is overwhelmingly bullish: 90% Buy (9 of 10) and 10% Hold. The mean price target is $20.71, median $20, with a high of $35 and low of $12. Canaccord's $18 target sits below the consensus mean but above the low. Over the past 30 days, QNRX has seen 3 upgrades and 0 downgrades. EPS revisions are mixed — 1 upward and 1 downward revision over 30 days. Insider buying in late August 2026 by the CEO, CFO, and a director totaling ~$180K aligns with the bullish analyst signal. Institutional buying is strong: Millennium Management added 47.3%, Barclays more than doubled its position, and Morgan Stanley and UBS also doubled. Short interest is elevated at 55.8% of float. The next earnings report is due November 4, 2026. The bottom line: a high-upside initiation from a mid-accuracy firm, reinforced by insider buys and institutional accumulation, but the extreme short interest adds a squeeze potential that could amplify moves.
Impact Score
Consensus & Targets
The consensus is heavily bullish: 2 Strong Buy, 7 Buy, 1 Hold, 0 Sell, 0 Strong Sell — 90% Buy/Strong Buy. Only 1 analyst rates it Hold. The direction is firmly positive, with no bearish ratings.
Current price: $3.90. Mean target: $20.71 (implied upside 431%). Median target: $20. High target: $35 (797% upside). Low target: $12 (208% upside). Canaccord's $18 target is 13% below the mean but still offers 361.5% upside. The wide range ($12-$35) reflects high uncertainty typical of a pre-revenue biotech.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-10-19 | Canaccord Genuity | initiate | Buy | $18.00 |
| 2026-10-12 | BTIG | initiate | Buy | $14.00 |
| 2026-09-23 | Lake Street | initiate | Buy | — |
| 2026-05-04 | LUCID CAPITAL MARKETS | initiate | Buy | — |
| 2024-03-15 | Maxim Group | maintain | Buy | $4.00 |
Over the past 30 days, QNRX has received 3 upgrades (including this initiation) and 0 downgrades. EPS revisions are mixed: 1 upward revision and 1 downward revision over 30 days. The current EPS estimate for the current fiscal year is -$7.17, unchanged from 7 and 30 days ago. The trend is neutral-to-positive on analyst actions but flat on earnings revisions.
Earnings Estimates
Next earnings: Nov 4, 2026
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0y | $-7.17 | $-7.89 — $-6.45 | $0.00 | ↑1 ↓0 |
| +1q | $-1.81 | $-2.18 — $-1.44 | $0.00 | ↑0 ↓0 |
| 0q | $-1.76 | $-2.05 — $-1.47 | $0.00 | ↑0 ↓0 |
| +1y | $-3.19 | $-4.45 — $-1.92 | $0.00 | ↑0 ↓0 |
Cross-Platform Signals
Insider buying is a strong bullish signal: CEO Anthony Culverwell bought ~$30K, CFO Sally Lawlor bought ~$50K, and director Michael Myers bought ~$100K — all on August 31, 2026. This aligns with the analyst initiation. Institutional buying is robust: Millennium Management added 47.3% ($544K), Barclays more than doubled (+1,551%, $104K), and Morgan Stanley and UBS both doubled. Short interest is extremely high at 55.8% of float, creating a potential squeeze catalyst. No congressional trades are recorded. The convergence of insider buys, institutional accumulation, and bullish analyst coverage is a powerful positive signal, though the short interest adds a binary risk.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $4.04 | awaiting T+5 | — | $4.01 (−0.74%) |
Oct 19, 2026 7d ago | ANALYST-UPGRADE | $3.98 $4.01 | ▲ +0.75% | ▲ +0.90% | $4.01 (+0.75%) |
Oct 14, 2026 12d ago | 8-K | $4.10 $3.99 | ▼ −2.68% | ▼ −3.14% | $4.01 (−2.20%) |
Oct 12, 2026 14d ago | ANALYST-UPGRADE | $4.36 $3.98 | ▼ −8.72% | ▼ −6.81% | $4.01 (−8.03%) |
Oct 7, 2026 19d ago | SC 13G/A | $4.55 $4.03 | ▲ +11.43% | ▲ +11.15% | $4.01 (+11.87%) |
Oct 2, 2026 24d ago | DEF 14A | $4.56 $4.36 | ▼ −4.28% | ▼ −4.70% | $4.01 (−11.96%) |
Sep 28, 2026 29d ago | EFFECT | $5.26 $4.56 | ▲ +13.40% | ▲ +14.61% | $4.01 (+23.76%) |
Sep 22, 2026 4w ago | Press Release | $7.01 $4.88 | ▼ −30.39% | ▼ −29.20% | $4.01 (−42.80%) |
Sep 18, 2026 5w ago | S-3 | $6.90 $5.26 | ▲ +23.77% | ▲ +22.75% | $4.01 (+41.88%) |
Sep 1, 2026 7w ago | Insider Cluster | $6.74 $6.90 | ▲ +2.37% | ▲ +3.33% | $4.01 (−40.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers